Results 131 to 140 of about 2,121,257 (344)
New views on the geology of the Bachav-Borzhav subcover of the Duklyan-Monthern cover
Вісник Харківського національного університету імені В.Н. Каразіна. Серія Геологія. Географія. ЕкологіяStatement of the general problem. The article considers the situation that has developed in the Bachava-Borzhav sub-nave of the Duklja-Chornohora nappe, due to the previously undetermined nature of the relationship between the deposits of the Lower ...
Myroslav Pavlyuk +3 more
doaj +1 more source
Test suite assessment of safety-critical systems using safety tactics and fault-based mutation testing [PDF]
Havva Gülay Gürbüz +3 more
openalex +1 more source
Molecular Oncology, EarlyView.Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source